Aclaris Therapeutics (ACRS) Profit After Tax (2014 - 2026)
Aclaris Therapeutics' (ACRS) quarterly Profit After Tax came in at -$19.8 million in Q1 2026, down 34.42% year-on-year from -$30.2 million in Q1 2025, and little changed quarter-over-quarter from -$19.8 million in Q4 2025.
Aclaris Therapeutics (ACRS) Profit After Tax (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Profit After Tax history runs 13 years deep, the most recent figure standing at -$19.8 million for Q1 2026.
- On a quarterly basis, Profit After Tax fell 34.42% year-over-year to -$19.8 million in Q1 2026; TTM through Mar 2026 was -$69.5 million, a 46.45% increase from a year earlier, with the FY2025 full-year figure at -$64.9 million, up 50.84% from the prior year.
- Profit After Tax steadied at -$19.8 million in Q1 2026 per ACRS's latest filing, from -$19.8 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$700000.0 in Q4 2023 and bottomed at -$96.6 million in Q4 2024.
- The 5-year median for Profit After Tax is -$19.8 million (2025), against an average of -$22.9 million.
- Across the five-year window, Profit After Tax soared 97.35% in 2023 and plunged 13693.14% in 2024, its largest moves.
- Year by year, Profit After Tax stood at -$26.4 million in 2022, then surged by 97.35% to -$700000.0 in 2023, then plunged by 13693.14% to -$96.6 million in 2024, then surged by 79.5% to -$19.8 million in 2025, then decreased by 0.15% to -$19.8 million in 2026.
- Per Business Quant, the three latest ACRS Profit After Tax figures stand at -$19.8 million (Q1 2026), -$19.8 million (Q4 2025), and -$14.5 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Aclaris Therapeutics | 672.39 Mn | 672.39 Mn | 1.60 Mn | -19.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.82 Mn |
| Dec 31, 2025 | -19.80 Mn |
| Sep 30, 2025 | -14.50 Mn |
| Jun 30, 2025 | -15.43 Mn |
| Mar 31, 2025 | -14.75 Mn |
| Dec 31, 2024 | -96.55 Mn |
| Sep 30, 2024 | -7.59 Mn |
| Jun 30, 2024 | -10.99 Mn |
| Mar 31, 2024 | -16.94 Mn |
| Dec 31, 2023 | -700,000.00 |
| Sep 30, 2023 | -29.28 Mn |
| Jun 30, 2023 | -29.57 Mn |
| Mar 31, 2023 | -28.16 Mn |
| Dec 31, 2022 | -26.39 Mn |
| Sep 30, 2022 | -19.95 Mn |
| Jun 30, 2022 | -20.53 Mn |
| Mar 31, 2022 | -18.79 Mn |
| Dec 31, 2021 | -22.93 Mn |
| Sep 30, 2021 | -20.97 Mn |
| Jun 30, 2021 | -18.16 Mn |